% | $
Quotes you view appear here for quick access.

ServiceSource International, Inc. Message Board

culleraa 29 posts  |  Last Activity: Aug 27, 2015 7:03 AM Member since: Apr 27, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Our "genius" is riding two horses

    by culleraa Jan 21, 2014 6:49 AM
    culleraa culleraa Aug 27, 2015 7:03 AM Flag

    Either 1+1 =2 and not much more, market anticipated this, or has not factored the merger in yet. Logic is as compelling now as it was when I wrote above. Price is same, but with cash offset. Market cap is a billion, too!... although the EV is now some 1.4 billion. RTU no longer has the RP drug program - didn't work - but has a fair pipeline for Greenleaf to talk about. Note his and other's background in immunology. Also, he integrated the company the right way, ie not into sales, yet.

  • culleraa culleraa Aug 27, 2015 6:47 AM Flag

    Nope. Still, likely a good thing not to have re-invested in stocks immediately!

  • Reply to


    by bonthomme Jul 14, 2015 9:45 AM
    culleraa culleraa Aug 19, 2015 6:47 AM Flag

    Quite. Live and learn. Still in the 4 months, if it is that long, you make 1.5% annualized on the buy of 12.59 without trading costs. Buyer/settler risk-free return is not much more...
    First one to see any cash from the settler gets a thumbs up!

  • Just to point out that this is not a simple 7 m stock valuation: Zack has some 1.6 m shares from the convertibles... add to that the options granted on some 0.7 m, so far. So real share count is around 6m+ in any change of control. Of course they all bring in cash... some 8 m maybe , so even at say 4 a share the EV would be just some 16 m ... neglecting debt. Comforting...

  • Reply to

    Moving in the right direction

    by who_gnu_1235 Aug 15, 2015 5:36 AM
    culleraa culleraa Aug 17, 2015 7:09 AM Flag

    Agree with the sentiment... as for predictions, we'll obviously have to see. They sound as optimistic as usual, but then they have to be! The "real" gross margin is up to 45% now, or again, which is not bad considering the cloud business... at least on a quick calc.
    This 20% growth needs to continue for a year or two... then the eps will turn positive like a rocket. On the other hand, though that before!

  • Reply to


    by bonthomme Jul 14, 2015 9:45 AM
    culleraa culleraa Aug 17, 2015 6:39 AM Flag

    Hi, thanks for replying! Before going on vacation, I mailed the broker and took them a while to respond: "My colleague at our corporate actions department informed me that Nordnet does not inform customers about this as customers are unable to do anything. We will send in the documents regarding the Israeli tax, so customers do not have to pay tax on the merger. So no action is needed from your part at this stage."
    As of today, stock value still in account ... but no cash, yet! Did you have better luck?

  • Reply to


    by bonthomme Jul 14, 2015 9:45 AM
    culleraa culleraa Jul 22, 2015 12:17 PM Flag

    Can you share where you got the notification from? So far, I have not received one... (process explains the wide spread...)

  • Reply to


    by bonthomme Jul 14, 2015 9:45 AM
    culleraa culleraa Jul 20, 2015 3:16 PM Flag

    last one i was involved in was meru a week or so ago: 7 days after closing til cash paid. Then it was a Delaware deal, quickly done.
    Here, SEC said Click filed for delisting, effective 15th.... with 1 shareholder...the buyer i presume! So, absolute min. 22nd i would expect on that basis.

  • Reply to

    20 millions

    by culleraa Jul 6, 2015 8:07 AM
    culleraa culleraa Jul 6, 2015 4:30 PM Flag

    When I see Csii trading same way, 99% sure reason is fear of DCB eating into atherectomy sales. Fear is real, but overdone! For SPnc also angioscore sales are at risk. This ruling knocks the chocolate copy for six though. I guess issue is DCB reps getting too much face time with the docs. Plain DCBs alone are not meant for difficult cases, so those should be ok medium term. Longer term, spnc has a dcb program, csii does not.

  • culleraa by culleraa Jul 6, 2015 8:07 AM Flag

    Last quarter guidance increased expenses by 20 m for DCB trials. 8-K increased loan available by 20 m - in line with increased spending. Court ruling gives 20 m (assuming win on appeal and can collect). QT had cash of 20 m at end of year... and with sales of 13 m last year growing at 100%, likely has sales of 20m right now. All quite convenient for the math.
    Recent price action can't have much to do with all of this, court win was hands-down, if it sticks. Trading in QT is halted and QT really has no way out. Sales are mostly in US so court will take those dollars if defendents do not pay up.... after and if all appeals lost.

  • Reply to

    Cash and go

    by culleraa Jun 30, 2015 7:55 AM
    culleraa culleraa Jun 30, 2015 3:50 PM Flag

    Given the deal noise, quarter should be in-line ie 14.5 or so. Expectations are really low. rightly, too. Analysts say this and next FY growth will have avg of 4 or 5%. If that changes in 2016 stock will get re-rated... So, no fast-food from this one...

  • culleraa by culleraa Jun 30, 2015 7:55 AM Flag

    Were some of these "deals" held up by perceived b/s weakness? Prob not... size-wise, none are significant... not even lumped together. This latest one is said to be a distri, but the company is also a manufacturer and potential end-user customer... but a distri just buys to own stock at a discount. New investors got a near 30% gain at one point, which implies the stock was cheap for that very reason. Still, this news flow is a refreshing change. And you never know if a "hockey stick" rise in demand has started, until it has!

  • 1 billion valuation today... sales some 50 m last year. Minor opthalmic surgery, but borderline benefit. Copy-cat competitor on its way, too.Major difference is that istent is covered by insurance. Even bigger difference is that Glaukos has the growth.. growth which Staar should have. Staar should and maybe can have a 1B valuation, too! Certainly the market will give it, if the business performs...

  • culleraa by culleraa Jun 25, 2015 4:24 PM Flag

    Not heard of this before Glaukos ipo. Same idea of an insert but a prostaglandin to lower iop. Wonder if "we" have thought of this... and complementing illuvian as an antagonist for the side effects, if they occur.

  • Reply to

    Time to get excited...?

    by culleraa Jun 10, 2015 7:36 AM
    culleraa culleraa Jun 22, 2015 8:14 AM Flag

    Only took 8 days to get a price target of 15 from someone. Actually, Benchmark was one of those that covered Siggie back in the boom years, they do not waste their time unless they think there will be action! Still, on an EV basis the value o f the co. has roughly doubled since last earnings - so can't expect too much more. That's unless merger fever finds Sigma as a target.

  • Reply to

    Heads Should Roll

    by mizzen13 Jun 16, 2015 1:56 PM
    culleraa culleraa Jun 17, 2015 4:34 PM Flag

    AGM voting results tell that active shareholders are rather satisfied with management. Strange...really!

  • The VCs got nothing like what they wanted in the ipo... but now they did, although they had to wait 3+ years for it. I would expect the rest of the shares to be distributed if the price holds up. This was a good move and price is ok, still!

  • SunTrust Robinson Humphrey assumes Supernus Pharmaceuticals (Nasdaq: SUPN) at Buy with a price target of $30. At least by streetinsider...

  • SEC filing can be interpreted as Fortinet started bidding at 4.1 and when they figured out DB was incapable of selling the company, or incompetent, gradually dropped the price. Insiders make a nice number anyway, cover themselves by saying the got a few more cents than Fortinets last offer, ha!

  • Now just went the one from last October. All this on quite low volume. Short interest was a historic high a few weeks ago, so all this action might just be unwinding. If not, quite a jump needed if there are still 5m shares short..

4.74-0.08(-1.66%)Aug 31 4:00 PMEDT